Treatment of NAFLD and NASH
Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.
1. A method for decreasing hepatic fat in a subject having a disease that is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) comprising administering a therapeutically effective amount of seladelpar or a salt thereof to the subject.
2. A method for decreasing hepatic fat in a subject having a disease that is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) comprising orally administering a therapeutically effective amount of seladelpar or a salt thereof to the subject.
3. The method of claim 2 where the daily dose of the seladelpar or a salt thereof administered to the subject is 20-200 mg, when the dose is calculated as seladelpar.
4. The method of claim 3 where the daily dose of the seladelpar or a salt thereof administered to the subject is 50-100 mg, when the dose is calculated as seladelpar.
5. The method of claim 2 where the seladelpar or a salt thereof is administered to the subject once/day.
6. The method of claim 2 where the disease is NAFLD.
7. The method of claim 2 where the disease is NASH.
8. A method for decreasing hepatic fat in a subject having a disease that is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) comprising orally administering a therapeutically effective amount of seladelpar L-lysine dihydrate salt to the subject.
9. The method of claim 8 where the daily dose of the seladelpar L-lysine dihydrate salt administered to the subject is 20-200 mg, when the dose is calculated as seladelpar.
10. The method of claim 9 where the daily dose of the seladelpar L-lysine dihydrate salt administered to the subject is 50-100 mg, when the dose is calculated as seladelpar.
11. The method of claim 8 where the seladelpar L-lysine dihydrate salt is administered to the subject once/day.
12. The method of claim 8 where the disease is NAFLD.
13. The method of claim 8 where the disease is NASH.